cyp3a4 mouse maxpab antibody Search Results


cyp3a4 mouse maxpab antibody  (Abnova)
90
Abnova cyp3a4 mouse maxpab antibody
Allele frequencies in SCF ( n = 363) and YK ( n = 350) populations compared with other populations globally
Cyp3a4 Mouse Maxpab Antibody, supplied by Abnova, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cyp3a4 mouse maxpab antibody/product/Abnova
Average 90 stars, based on 1 article reviews
cyp3a4 mouse maxpab antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cyp3a4 purified maxpab mouse polyclonal antibody b01p  (Abnova)
90
Abnova cyp3a4 purified maxpab mouse polyclonal antibody b01p
Allele frequencies in SCF ( n = 363) and YK ( n = 350) populations compared with other populations globally
Cyp3a4 Purified Maxpab Mouse Polyclonal Antibody B01p, supplied by Abnova, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cyp3a4 purified maxpab mouse polyclonal antibody b01p/product/Abnova
Average 90 stars, based on 1 article reviews
cyp3a4 purified maxpab mouse polyclonal antibody b01p - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Allele frequencies in SCF ( n = 363) and YK ( n = 350) populations compared with other populations globally

Journal: Clinical and Translational Science

Article Title: Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function

doi: 10.1111/cts.12970

Figure Lengend Snippet: Allele frequencies in SCF ( n = 363) and YK ( n = 350) populations compared with other populations globally

Article Snippet: CYP3A4 was detected with primary antibody, CYP3A4 Mouse MaxPab (Abnova, Taipei City, Taiwan), diluted (1:1,000) in blocking buffer (Tris‐buffered saline +0.2% Tween +7% nonfat milk), and secondary antibody, HRP‐conjugated anti‐mouse (Thermo Fisher) diluted (1:100,000) in blocking buffer +1% goat.

Techniques: Variant Assay

CYP3A4 protein content in lymphoblastoid cell lines (LCLs). Immunoblot of CYP3A4 and glyceraldehyde 3‐phosphate dehydrogenase (GAPDH) in LCLs with CYP3A4*1 / *1 , *1 / *3 , and *3 / *3 diplotypes (panel a). Quantitation of CYP3A4 normalized to GAPDH endogenous control (panel b). One‐way analysis of variance was used to compare CYP3A4 diplotypes

Journal: Clinical and Translational Science

Article Title: Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function

doi: 10.1111/cts.12970

Figure Lengend Snippet: CYP3A4 protein content in lymphoblastoid cell lines (LCLs). Immunoblot of CYP3A4 and glyceraldehyde 3‐phosphate dehydrogenase (GAPDH) in LCLs with CYP3A4*1 / *1 , *1 / *3 , and *3 / *3 diplotypes (panel a). Quantitation of CYP3A4 normalized to GAPDH endogenous control (panel b). One‐way analysis of variance was used to compare CYP3A4 diplotypes

Article Snippet: CYP3A4 was detected with primary antibody, CYP3A4 Mouse MaxPab (Abnova, Taipei City, Taiwan), diluted (1:1,000) in blocking buffer (Tris‐buffered saline +0.2% Tween +7% nonfat milk), and secondary antibody, HRP‐conjugated anti‐mouse (Thermo Fisher) diluted (1:100,000) in blocking buffer +1% goat.

Techniques: Western Blot, Quantitation Assay, Control

CYP3A4 protein content and activity in human liver microsomes (HLMs). CYP3A4 protein content (panel a) and CYP3A4 metabolic activity (panel b) by CYP3A4 diplotypes: CYP3A4*1 / *1 ( n = 245), *1 / *1G ( n = 64), and *1G / *1G ( n = 10). All incubations were completed in triplicate. Multivariable linear regression was used to compare protein content and activity between HLMs based on genotype, adjusting for site of sample collection

Journal: Clinical and Translational Science

Article Title: Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function

doi: 10.1111/cts.12970

Figure Lengend Snippet: CYP3A4 protein content and activity in human liver microsomes (HLMs). CYP3A4 protein content (panel a) and CYP3A4 metabolic activity (panel b) by CYP3A4 diplotypes: CYP3A4*1 / *1 ( n = 245), *1 / *1G ( n = 64), and *1G / *1G ( n = 10). All incubations were completed in triplicate. Multivariable linear regression was used to compare protein content and activity between HLMs based on genotype, adjusting for site of sample collection

Article Snippet: CYP3A4 was detected with primary antibody, CYP3A4 Mouse MaxPab (Abnova, Taipei City, Taiwan), diluted (1:1,000) in blocking buffer (Tris‐buffered saline +0.2% Tween +7% nonfat milk), and secondary antibody, HRP‐conjugated anti‐mouse (Thermo Fisher) diluted (1:100,000) in blocking buffer +1% goat.

Techniques: Activity Assay

Multiple linear regression analysis of covariates with log CYP3A4 protein content and log CYP3A4 activity in human liver microsomes, adjusting for variables independently associated with log CYP3A4 protein content and activity

Journal: Clinical and Translational Science

Article Title: Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function

doi: 10.1111/cts.12970

Figure Lengend Snippet: Multiple linear regression analysis of covariates with log CYP3A4 protein content and log CYP3A4 activity in human liver microsomes, adjusting for variables independently associated with log CYP3A4 protein content and activity

Article Snippet: CYP3A4 was detected with primary antibody, CYP3A4 Mouse MaxPab (Abnova, Taipei City, Taiwan), diluted (1:1,000) in blocking buffer (Tris‐buffered saline +0.2% Tween +7% nonfat milk), and secondary antibody, HRP‐conjugated anti‐mouse (Thermo Fisher) diluted (1:100,000) in blocking buffer +1% goat.

Techniques: Activity Assay

CYP3A4‐mediated vitamin D hydroxylation. Ratio of serum 4ß,25(OH) 2 D 3 and 25(OH)D 3 in unrelated participants from the Yukon‐Kuskokwim (YK) Delta ( n = 514) by CYP3A4 diplotypes: individuals with no CYP3A4*1G ( n = 457) and individuals who at least one copy of CYP3A4*1G ( n = 57). A t ‐test was used to compare the two groups

Journal: Clinical and Translational Science

Article Title: Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function

doi: 10.1111/cts.12970

Figure Lengend Snippet: CYP3A4‐mediated vitamin D hydroxylation. Ratio of serum 4ß,25(OH) 2 D 3 and 25(OH)D 3 in unrelated participants from the Yukon‐Kuskokwim (YK) Delta ( n = 514) by CYP3A4 diplotypes: individuals with no CYP3A4*1G ( n = 457) and individuals who at least one copy of CYP3A4*1G ( n = 57). A t ‐test was used to compare the two groups

Article Snippet: CYP3A4 was detected with primary antibody, CYP3A4 Mouse MaxPab (Abnova, Taipei City, Taiwan), diluted (1:1,000) in blocking buffer (Tris‐buffered saline +0.2% Tween +7% nonfat milk), and secondary antibody, HRP‐conjugated anti‐mouse (Thermo Fisher) diluted (1:100,000) in blocking buffer +1% goat.

Techniques: